Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…Abstract Number: 2127 • ACR Convergence 2023
Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of developing certain cancers, including bladder cancer (Beydon et al. 20231). However, few studies have…Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…Abstract Number: 2512 • ACR Convergence 2023
Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…Abstract Number: 2138 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Background/Purpose: Cancer immunotherapy is a newly-approved approach in the management of advanced malignancies. Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer…Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…Abstract Number: 1914 • 2018 ACR/ARHP Annual Meeting
Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients
Background/Purpose: Rheumatologists are increasingly called upon to manage the autoimmune side effects of immune-checkpoint inhibitors (ICIs). However, these new entities are poorly understood and treatment…Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting
Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience
Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…